Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report), Pro Medicus Limited (PMCUF – Research Report) and Immunic (IMUX – Research Report).
Roche Holding AG (RHHVF)
In a report released today, Peter Welford from Jefferies maintained a Hold rating on Roche Holding AG, with a price target of CHF305.00. The company’s shares closed last Wednesday at $317.70.
According to TipRanks.com, Welford is a 5-star analyst with an average return of
Roche Holding AG has an analyst consensus of Hold, with a price target consensus of $331.39, representing a 6.2% upside. In a report issued on July 18, Morgan Stanley also maintained a Hold rating on the stock with a CHF310.00 price target.
See today’s best-performing stocks on TipRanks >>
Pro Medicus Limited (PMCUF)
Goldman Sachs analyst Chris Cooper upgraded Pro Medicus Limited to Buy today. The company’s shares closed last Friday at $44.00.
According to TipRanks.com, Cooper is a 2-star analyst with an average return of
Currently, the analyst consensus on Pro Medicus Limited is a Hold with an average price target of $37.59.
Immunic (IMUX)
Wedbush analyst Andreas Argyrides reiterated a Buy rating on Immunic today and set a price target of $5.00. The company’s shares closed last Wednesday at $2.18, close to its 52-week low of $1.11.
According to TipRanks.com, Argyrides is a 4-star analyst with an average return of
Currently, the analyst consensus on Immunic is a Strong Buy with an average price target of $13.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RHHVF:
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions’ base business; Group sales and profit reflect declining demand for COVID-19 products
- Alnylam price target lowered to $233 from $247 at Bernstein
- Alnylam enters pact with Roche to develop, commercialize zilebesiran
- Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
- CHMP recommends Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
